Comparing Syros Pharmaceuticals (SYRS) & Chiasma (CHMA)
Syros Pharmaceuticals (NASDAQ: SYRS) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.
Earnings & Valuation
This table compares Syros Pharmaceuticals and Chiasma’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Syros Pharmaceuticals||$1.42 million||364.68||-$48.99 million||($2.13)||-9.26|
Chiasma has higher revenue, but lower earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Syros Pharmaceuticals has a beta of -4.02, indicating that its share price is 502% less volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
This table compares Syros Pharmaceuticals and Chiasma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
49.7% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.2% of Chiasma shares are owned by institutional investors. 3.2% of Chiasma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Syros Pharmaceuticals and Chiasma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Syros Pharmaceuticals currently has a consensus target price of $21.77, indicating a potential upside of 10.39%. Given Syros Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Syros Pharmaceuticals is more favorable than Chiasma.
Chiasma beats Syros Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.